Talroo Announces CEO Transition to Support Next Phase of Growth
AUSTIN, Texas--(BUSINESS WIRE)--Talroo, the data-driven talent matching platform for frontline and skilled trades hiring, today announced a leadership transition: Thad Price has stepped down as Chief Executive Officer, and Bruce Ge, Talroo's Founder and Chairman of the Board, has been appointed CEO, effective immediately.
'Over the past several years, Talroo has established itself as a leader in talent acquisition, matching job seekers with employers,' said Ge. 'Driven by the strength of our team and platform, we now help thousands of employers reach qualified candidates more efficiently. Thad has contributed to that progress by offering strategic input and perspective during a period of growth and change.'
Ge, who founded Talroo in 2010, brings deep expertise in technology, product development, and innovation. As CEO, he will lead the company through its next phase, with a focus on product innovation, customer trust, and operational excellence.
'Our mission remains the same—empowering employers to connect with talent others can't reach—but our ambition continues to grow,' said Ge. 'We're moving forward with clarity, intensity, and a renewed commitment to our customers, our team, and our future.'
The leadership transition was approved by the Board of Directors and is effective as of May 27, 2025.
About Talroo
Talroo is a data-driven talent matching platform built to help businesses source frontline and skilled trades workers that traditional job sites overlook. By leveraging real-time applicant tracking system (ATS) data and AI-driven technology, Talroo connects businesses with high-intent job seekers faster and at a lower cost. Powering millions of job searches daily, Talroo optimizes hiring outcomes through its proprietary Apply Intelligence™ technology, apply signals, and behavioral insights.
Talroo has been recognized as a leader in talent acquisition innovation, most recently winning the HR Tech Award for Best Frontline-Focused Solution in Talent Acquisition from Lighthouse Research & Advisory and the Gold Stevie® Award for Technical Innovation of the Year from the American Business Awards. Talroo has also been named a Leader in Recruitment Marketing and Easiest to Do Business With by G2, based on customer satisfaction and peer reviews.
Learn more at www.talroo.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 hours ago
- Business Wire
ABL Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abacus Global Management, Inc. ('Abacus' or 'the Company') (NASDAQ: ABL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abacus is the subject of a report issued by Morpheus Research on June 4, 2025, titled: 'Abacus Global Management: This $794 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue by Systematically Underestimating When People Will Die.' According to the report, the Company changed its portfolio valuation methodology to make it appear more profitable than it actually is. The report also alleges that the Company uses unusual methodologies to calculate life expectancy estimates and its co-founders have 'red flags' in their past. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Upturn
16 hours ago
- Business Upturn
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extended-Release (ER) Tablets in 150 mg, 300 mg, and 600 mg strengths. These tablets are the generic equivalent of Oxtellar XR® ER Tablets by Supernus Pharmaceuticals and are indicated for the treatment of partial-onset seizures in patients aged 6 years and above. Lupin's version of the drug will be manufactured at its Nagpur facility in India. According to IQVIA MAT April 2025 data, Oxcarbazepine ER Tablets (RLD Oxtellar XR®) recorded estimated annual sales of USD 206 million in the United States, underscoring the potential market opportunity for Lupin. Headquartered in Mumbai, Lupin is a leading global pharmaceutical company with a strong footprint in the U.S. and India. The company focuses on a broad range of therapy areas including central nervous system disorders, respiratory, cardiovascular, anti-infective, and women's health. It operates 15 manufacturing sites and 7 research centers globally, supported by over 23,000 employees. Lupin continues to expand its U.S. portfolio of complex generics and remains committed to delivering high-quality, affordable medicines that improve health outcomes for patients around the world. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Insider
a day ago
- Business Insider
Opendoor Technologies seeks reverse stock split
Opendoor Technologies (OPEN) filed a preliminary proxy statement. The proxy statement was furnished in connection with the solicitation of proxies by Opendoor's Board of Directors for use at the company's Special Meeting of Stockholders to be held on Monday, July 28, 2025, at 9:30 a.m. Pacific Time. 'Our Board has adopted and is recommending that our stockholders approve amendments to our Certificate of Incorporation, to effect a reverse stock split of our common stock at a ratio ranging from any whole number between 1-for-10 and 1-for-50, with the exact ratio within such range to be determined by the Board in its discretion, subject to the Board's authority to determine when to file the amendment and to abandon the other amendments notwithstanding prior stockholder approval of such amendments.' Confident Investing Starts Here:
